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relation between GGT and CKD by gender, alcohol intake, 
and BMI categories also showed a consistent null associa-
tion. In summary, there was no association between increas-
ing levels of serum GGT and CKD in a sample of US adults. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
  -Glutamyltransferase (GGT) is a cell-surface enzyme 
that plays a major role in the extracellular catabolism of 
glutathione (GSH), the main antioxidant in mammalian 
cells  [1, 2] . Serum levels of GGT may therefore be consid-
ered a marker of oxidative stress  [3] . Previous epidemio-
logical studies have reported associations between elevat-
ed GGT levels and peripheral arterial disease  [4, 5] and 
cardiovascular disease  [6] . Studies have also shown that 
higher GGT levels are related to diabetes mellitus  [7, 8] 
and hypertension  [8, 9] , which are risk factors for chron-
ic kidney disease (CKD). However, few studies have ex-
amined the association between GGT levels and CKD. 
We examined the association between serum GGT levels 
and CKD in participants of the National Health and Nu-
trition Examination Survey (NHANES) 1999–2002, a 
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 Abstract 
 Background/Aim: Serum   -glutamyltransferase (GGT), a 
biomarker of oxidative stress, is associated with an increased 
risk of diabetes and hypertension. However, it is not known 
whether higher serum GGT is independently associated with 
chronic kidney disease (CKD). Therefore, we examined the 
association between serum GGT levels and CKD in a repre-
sentative sample of US adults.  Methods: We conducted a 
cross-sectional study of 9,516 National Health and Nutrition 
Examination Survey 1999–2002 participants  6 18 years of 
age (52.40% women). Serum GGT was categorized into quar-
tiles for the analysis. CKD (n = 622) was defined as an esti-
mated glomerular filtration rate of  ! 60 ml/min/1.73 m 2 .  Re-
sults and Conclusion: Higher serum GGT levels were not as-
sociated with CKD after adjusting for age, sex, race/ethnicity, 
education levels, smoking, alcohol intake, body mass index 
(BMI), diabetes, hypertension and serum cholesterol. Com-
pared to quartile 1 of GGT, the odds ratio (95% confidence 
interval) of CKD associated with quartile 4 was 1.02 (0.81–
1.28); p trend = 0.377. Subgroup analyses that examined the 
 Received: September 16, 2009 
 Accepted: November 3, 2009 
 Published online: January 13, 2010 
 Dr. Anoop Shankar 
 Department of Community Medicine 
 West Virginia University School of Medicine 
 PO Box 9190, Morgantown, WV 26506-9190 (USA) 
 Tel. +1 304 293 0199, Fax +1 304 293 6685, E-Mail ashankar  @  hsc.wvu.edu 
 © 2010 S. Karger AG, Basel
1420–4096/10/0331–0001$26.00/0 
 Accessible online at:
www.karger.com/kbr 
 Teppala /Shankar /Li /Wong /Ducatman Kidney Blood Press Res 2010;33:1–62
nationally representative sample of adults in the United 
States, after adjusting for several important confounders, 
including alcohol intake.
 Methods 
 Study Participants 
 The NHANES 1999–2002 was a nationally representative 
sample of the non-institutionalized civilian population of the 
United States. A detailed summary of the procedures involved in 
NHANES 1999–2002 has been published and is available online 
 [10, 11] . In brief, the NHANES survey included a stratified multi-
stage probability sample. Selection was based on counties, blocks, 
households and individuals within households, and included the 
oversampling of non-Hispanic Blacks and Mexican-Americans in 
order to provide stable estimates of these groups. Subjects were 
required to sign a consent form before their participation, and ap-
proval was obtained from the Human Subjects Committee in the 
US Department of Health and Human Service.
 Overall, 11,441 adults  6 18 years of age participated in the in-
terview and examination components of NHANES 1999–2002. 
Of these participants, serum creatinine and GGT levels are avail-
able for 9,836 (85.97%) participants. Out of these, we further ex-
cluded 320 subjects with missing covariable data (e.g., serum cho-
lesterol). This resulted in 9,516 participants (52.4% women), 622 
of whom had CKD.
 Main Outcome of Interest: Presence of CKD 
 The 4-variable Modification of Diet in Renal Diseases (MDRD) 
study equation was used to estimate glomerular filtration rate 
(eGFR) from serum creatinine  [12] . CKD was defined as eGFR of 
 ! 60 ml/min/1.73 m 2 , consistent with National Kidney Founda-
tion Kidney Disease Outcomes Quality Initiative (KDOQI) 
 6 stage 3 CKD  [13] .
 Exposure Measurements 
 Age, gender, race/ethnicity, smoking status, alcohol intake
(g/day), level of education, history of diabetes and oral hypogly-
cemic intake or insulin administration, and antihypertensive 
medication use were assessed using a questionnaire. Individuals 
who had not smoked  6 100 cigarettes in their lifetimes were con-
sidered never smokers; those who had smoked  6 100 cigarettes in 
their lifetimes were considered former smokers if they answered 
negatively to the question ‘Do you smoke now?’ and current smok-
ers if they answered affirmatively. Body mass index (BMI) was 
calculated as weight in kilograms divided by height in meters 
squared.
 Rigorous procedures with quality control checks were used in 
blood collection and details about these procedures are provided 
in the NHANES Laboratory/Medical Technologists Procedures 
Manual  [11] . Serum GGT concentration was assayed with a Hita-
chi 737 Analyzer (Boehringer-Mannheim Diagnostics, Indianap-
olis, Ind., USA) at White Sands Research Center, Alamogordo, N. 
Mex., USA; details of laboratory measurements are available on-
line  [10] . Serum total cholesterol was measured enzymatically. Se-
rum glucose was measured using the modified hexokinase meth-
od at the University of Missouri Diabetes Diagnostic Laboratory. 
Diabetes was defined based on the guidelines of the American 
Diabetes Association as a serum glucose  6 126 mg/dl after fasting 
for a minimum of 8 h, a serum glucose  6 200 mg/dl for those who 
fasted  ! 8 h before their NHANES visit, or a self-reported current 
use of oral hypoglycemic medication or insulin. Seated systolic 
and diastolic blood pressures were measured using a mercury 
sphygmomanometer according to the American Heart Associa-
tion and Seventh Joint National Committee (JNC7) recommen-
dations  [10, 14] . Up to three measurements were averaged for sys-
tolic and diastolic pressures. Patients were considered hyperten-
sive if they reported current blood pressure-reducing medication 
use and/or had systolic blood pressures  6 140 mm Hg and/or dia-
stolic blood pressures  6 90 mm Hg  [14] .
 Statistical Analysis 
 Serum GGT was analyzed both as a continuous variable and a 
categorical variable. For the analysis as a continuous variable, se-
rum GGT values were log transformed (base 2) as a result of their 
skewed distribution. As physiologically normal serum GGT levels 
vary in men and women, we categorized serum GGT level as 
quartiles by gender (men:  ! 18, 18–25, 26–38,  1 38 U/l; women: 
 ! 13, 13–17, 18–25,  1 25 U/l).
Table 1. Baseline characteristics of the study population
Characteristics Whole cohort (n = 9,516)





Non-Hispanic Whites 4,468 (46.9)




Below high school 3,352 (35.2)
High school 2,280 (23.9)
Above high school 3,884 (40.8)
Smoking, %
Never smoker 5,436 (57.1)
Former smoker 2,250 (23.6)
Current smoker 1,830 (19.2)
Alcohol intake, %
Current non-drinker 7,197 (75.6)
Current drinker 2,319 (24.4)
Alcohol intake, g 8.9280.3
Body mass index 27.9780.1
Diabetes mellitus, % 817 (9.2)
Hypertension, % 3,021 (31.8)
Total cholesterol, mg/dl 197.2180.4
Mean GGT, U/l 30.5580.5
Mean GFR, ml/min/1.73 m2 107.2280.4
Data presented are number (percentages) or mean values 8 
SE, as appropriate for the variable.
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 The odds ratio (OR; 95% confidence interval (CI)) of CKD for 
each GGT quartile was calculated by taking the lowest quartile as 
the referent, using multivariable logistic regression models. We 
used two models: the age- and sex-adjusted model and the multi-
variable model, additionally adjusting for race/ethnicity (non-
Hispanic Whites, non-Hispanic Blacks, Mexican-Americans, 
others), education categories (below high school, high school, 
above high school), smoking (never smoker, former smoker, cur-
rent smoker), alcohol intake (g/day), BMI, diabetes mellitus (ab-
sent, present), hypertension (absent, present), and total serum 
cholesterol (mg/dl). Trends in the OR of CKD across increasing 
serum GGT category were determined modeling GGT categories 
as an ordinal variable. As GGT levels are related to gender  [15] , 
alcohol intake  [16] and BMI,  [17] , subgroup analyses taking these 
factors into consideration were performed. Also, we performed 
additional analyses after excluding subjects with self-reported 
cardiovascular disease and GGT levels indicative of cholestasis 
( 1 80 U/l) to know whether the observed findings remained un-
changed. Sample weights that account for the unequal probabili-
ties of selection, oversampling, and non-response were applied for 
all analyses using SUDAAN (version 8.0; Research Triangle Insti-
tute, Research Triangle Park, N.C., USA) and SAS (Version 9.2; 
SAS Institute, Cary, N.C., USA) software; SEs were estimated us-
ing the Taylor series linearization method.
 Results 
 Among 9,516 adults  6 18 years of age included in the 
current analyses, 622 (6.53%) individuals had CKD.  Ta-
ble 1 presents the baseline characteristics of the study 
population. Mean age was approximately 46 years in men 
and 45 years in women.  Table 2 presents the ORs of CKD 
by increasing levels of the GGT distribution. There was 
no association between increasing levels of GGT and 
CKD in both the age and sex-adjusted model (p trend = 
Table 2. Association between serum GGT levels and CKD
Serum GGT quartiles









Quartile 1 2,364 148 1 (referent) 1 (referent)
Quartile 2 2,555 174 0.73 (0.51, 1.02) 0.67 (0.49, 0.93)
Quartile 3 2,226 139 0.97 (0.72, 1.30) 0.94 (0.74, 1.19)
Quartile 4 2,371 161 1.01 (0.79, 1.29) 1.02 (0.81, 1.28)
p trend 0.312 0.377
log-transformed serum GGT, U/l 9,516 622 0.99 (0.84, 1.17) 1.01 (0.85, 1.20)
1 GGT quartiles in men, quartile 1–4: <18, 18–25, 26–38, >38 U/l, and in women quartile 1–4: <13, 13–17, 18–25, >25 U/l.
2 Adjusted for age (years), race-ethnicity (non-Hispanic Whites, non-Hispanic Blacks, Mexican-Americans, others), education cat-
egories (below high school, high school, above high school), smoking (never, former, current), alcohol intake (never, former, current), 
BMI (normal, overweight, obese), diabetes (absent, present), hypertension (absent, present) and serum total cholesterol (mg/dl).













Quartile 1 1,299 53 1 (referent)
Quartile 2 1,286 90 0.70 (0.44, 1.11)
Quartile 3 1,152 85 0.97 (0.71, 1.32)
Quartile 4 1,249 101 0.96 (0.78, 1.18)
p trend 0.498
log-transformed
serum GGT, U/l 4,986 329 0.95 (0.78, 1.16)
Men
Quartile 1 1,065 95 1 (referent)
Quartile 2 1,269 84 0.65 (0.41, 1.03)
Quartile 3 1,074 54 0.89 (0.64, 1.24)
Quartile 4 1,122 60 1.04 (0.82, 1.32)
p trend 0.668
log-transformed
serum GGT, U/l 4,530 293 1.03 (0.83, 1.28)
1 GGT quartiles in men, quartile 1–4: <18, 18–25, 26–38, >38 
U/l, and in women quartile 1–4: <13, 13–17, 18–25, >25 U/l.
2 Adjusted for age (years), race-ethnicity (non-Hispanic 
Whites, non-Hispanic Blacks, Mexican-Americans, others), edu-
cation categories (below high school, high school, above high 
school), smoking (never, former, current), alcohol intake (never, 
former, current), BMI (normal, overweight, obese), diabetes (ab-
sent, present), hypertension (absent, present) and serum total 
cholesterol (mg/dl).
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0.312) and the multivariable adjusted models (p trend = 
0.377), and the magnitude of OR hovered around 1, con-
sistent with a null effect. This relationship persisted even 
when serum GGT was analyzed as a continuous vari-
able.
 In  table 3 , we present the gender-specific analyses for 
the association between increasing GGT levels and CKD. 
Here also, consistent with the findings for the whole co-
hort, there was no clear association between increasing 
GGT levels and CKD either among men (p trend = 0.668) 
or among women (p trend = 0.498).
 Tables 4 and  5 examined the association between in-
creasing serum GGT levels and CKD within subgroups 
of alcohol intake (current non-drinker, current drinker) 
and BMI (normal weight, overweight/obese). Consistent 
with findings for the whole cohort, there was no clear as-
sociation between increasing GGT levels and CKD, either 
among current non-drinkers (p trend = 0.378) or current 
drinkers (p trend = 0.627), or among normal weight sub-
jects (p trend = 0.418) or overweight/obese subjects
(p trend = 0.958).
Table 4. Association between increasing serum GGT levels and CKD by alcohol intake status
Serum GGT
quartiles cohort1









Quartile 1 1,921 (122) 1 (referent) 443 (26) 1 (referent)
Quartile 2 1,936 (146) 0.77 (0.56, 1.05) 619 (28) 0.63 (0.21, 1.89)
Quartile 3 1,653 (123) 0.85 (0.62, 1.15) 573 (16) 0.97 (0.46, 2.04)
Quartile 4 1,687 (133) 0.96 (0.62, 1.49) 684 (28) 1.01 (0.62, 1.64)
p trend 0.378 0.6024 0.627
1 GGT quartiles in men, quartile 1–4: <18, 18–25, 26–38, >38 U/l, and in women quartile 1–4: <13, 13–17, 
18–25, >25 U/l.
2 Adjusted for age (years), sex (men, women), race-ethnicity (non-Hispanic Whites, non-Hispanic Blacks, 
Mexican-Americans, others), education categories (below high school, high school, above high school), smok-
ing (never, former, current), BMI (normal, overweight, obese), diabetes (absent, present), hypertension (absent, 
present) and serum total cholesterol (mg/dl).
Table 5. Association between increasing serum GGT levels and CKD by BMI
Serum GGT
quartiles cohort1










Quartile 1 1,264 (64) 1 (referent) 1,100 (84) 1 (referent)
Quartile 2 969 (43) 0.56 (0.38, 0.84) 1,586 (131) 1.06 (0.52, 2.19)
Quartile 3 596 (51) 0.66 (0.45, 0.96) 1,630 (88) 0.98 (0.50, 1.92)
Quartile 4 497 (32) 1.04 (0.57, 1.89) 1,874 (129) 0.87 (0.40, 1.92)
p trend 0.418 0.958
1 GGT quartiles in men, quartile 1–4: <18, 18–25, 26–38, >38 U/l, and in women quartile 1–4: <13, 13–17, 
18–25, >25 U/l.
2 Adjusted for age (years), sex (men, women), race-ethnicity (non-Hispanic Whites, non-Hispanic Blacks, 
Mexican-Americans, others), education categories (below high school, high school, above high school), smok-
ing (never, former, current), alcohol intake (never, former, current), diabetes (absent, present), hypertension 
(absent, present) and serum total cholesterol (mg/dl).
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 We performed several supplementary analyses to con-
firm the robustness of our findings. First, we repeated the 
main analysis after excluding subjects with history of car-
diovascular disease; the results were essentially the same. 
Compared to quartile 1 of GGT, the multivariable OR 
(95% CI) of CKD was 0.75 (0.44–1.28) for quartile 2, 1.03 
(0.63–1.68) for quartile 3, 0.96 (0.58–1.59) for quartile 4; 
p trend = 0.541. Second, we repeated the main analysis 
after excluding subjects with very high serum GGT levels 
( 1 80 U/l), indicative of cholestasis; here also the results 
were similar to our main findings. Compared to quartile 
1 of GGT, the multivariable OR (95% CI) of CKD was 0.87 
(0.52–1.45) for quartile 2, 0.96 (0.70–1.32) for quartile 3, 
0.91 (0.76–1.09) for quartile 4; p trend = 0.392.
 Discussion 
 In our analysis of a nationally representative sample of 
US adults, we found no association between increasing 
GGT levels and CKD. The magnitude of ORs for the as-
sociation between increasing quartiles of GGT and CKD 
was consistent with an overall null association when ad-
justed initially for age, sex, race/ethnicity, and then fur-
ther for education, smoking, alcohol intake, BMI, diabe-
tes, hypertension, and total cholesterol. Subsequent sub-
group analyses by gender, alcohol intake, and BMI 
categories yielded similar results. In subsidiary analyses 
that excluded subjects with cardiovascular disease and 
cholestasis from the study population, the results yet 
again showed no discernable association over the range 
of serum GGT quartiles and CKD.
 Previous studies have shown that higher GGT levels in 
serum predicted the risk of cardiovascular disease  [6, 18] . 
Studies have also shown that serum GGT levels are re-
lated to diabetes mellitus  [7] and hypertension  [8, 9] 
which are strong, independent risk factors for CKD. 
However, few studies have examined the putative asso-
ciation between serum GGT and CKD.
 Ryu et al.  [19] in a recent prospective study from Korea 
reported a positive association between serum levels of 
GGT and CKD. They found that the association between 
GGT and CKD was independent of factors such as diabe-
tes and hypertension. However, this study included only 
men and examined an occupational cohort of workers 
from a semiconductor manufacturing plant. It is not clear 
if these results are also applicable to women. Second, the 
fact that they studied a cohort of healthy workers and not 
a community-based sample could have biased their find-
ings (e.g. healthy worker effect). Third, as GGT levels are 
influenced by alcohol and diet, findings from Asian pop-
ulations may not be directly applicable to Western popu-
lations with different alcohol intake and dietary pat-
terns.
 In this context, the current study is the first report on 
the association between serum GGT and CKD in a large 
sample of US adults. It is worth noting that in contrast to 
the Korean study  [19] , we examined both men and wom-
en, and studied a wider range of alcohol intake patterns, 
representative of typical Western populations. Our re-
sults, however, indicate no association between increas-
ing serum GGT levels and CKD. The large sample size 
available for the current analyses, our ability to adjust for 
all potential confounders, and the consistency of these 
results of an overall null association suggest that our 
findings are less likely due to chance. Furthermore, the 
observed null association was consistently present in sup-
plementary analyses where we excluded subjects with 
cardiovascular disease and high GGT levels indicative of 
cholestasis.
 The key strengths of our study include the following. 
As we examined a representative sample of US adults, 
these results are generalizable to US adults. Furthermore, 
all data were collected following rigorous methodology, 
including a study protocol with standardized quality 
control checks  [11] . The main limitation of our study is 
the cross-sectional nature of NHANES, which precludes 
conclusions regarding the temporal nature of the asso-
ciation between serum GGT and CKD. Also, another 
study limitation that could have biased our results is the 
lack of information on waist circumference or visceral fat 
accumulation as a measure of obesity.
 In conclusion, we found no association between in-
creasing serum GGT levels and CKD in a sample of US 
adults. These findings suggest that the previously report-
ed association between serum GGT and CKD may be re-
lated to confounding factors such as gender, alcohol in-
take, BMI, diabetes, and hypertension. Our study does 
not support measuring serum GGT for the purpose of 
CKD prediction in Western populations.
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